Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma

King J, de la Cruz J, Lutzky J. Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP). J Immunother Cancer. 2017;5:19. https://doi.org/10.1186/s40425-017-0224-7.

Youssef A, Kasso N, Torloni AS, Stanek M, Dragovich T, Gimbel M, et al. Thrombotic thrombocytopenic purpura due to checkpoint inhibitors. Case Rep Hematol. 2018;2018:2464619. https://doi.org/10.1155/2018/2464619.

Honjo O, Kubo T, Sugaya F, Nishizaka T, Kato K, Hirohashi Y, et al. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer. 2019;7(1):97. https://doi.org/10.1186/s40425-019-0582-4.

Chang JC, Naqvi T. Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer. Oncologist. 2003;8(4):375–80. https://doi.org/10.1634/theoncologist.8-4-375.

Nicholson MC, Pavenski K, Trinkaus M. A case for consideration by apheresis practitioners: melanoma and PD-1 inhibitor treatment in a patient with multiple relapses of immune thrombotic thrombocytopenic purpura. Transfus Apher Sci. 2019;58(2):123–4. https://doi.org/10.1016/j.transci.2019.03.001.